You are here

Magnetic Flow Sorter for Pancreatic Islet Isolation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK072647-04A1
Agency Tracking Number: R44DK072647
Amount: $2,671,250.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Greenville, IN 47124-9515
United States
DUNS: 621970383
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (812) 923-9591
Business Contact
Phone: (812) 923-9591
Research Institution

DESCRIPTION (provided by applicant): Techshot, Inc. has successfully completed SBIR Phase I and Phase II research demonstrating that magnetically labeled porcine islets of Langerhans can be isolated from contaminating exocrine tissue by flow sorting usinga quadrupole magnetic separator ( Quadrasep ) designed for that purpose. Magnetically sorted islets are superior in morphology and physiology to those isolated by the presently used centrifugation method. A Phase IIB Competing Renewal project is proposed in which Techshot will collaborate with scientists at the University of Arizona, University of Louisville, IKOTECH LLC and Vitacyte LLC to prepare this technology for regulatory approval and commercialization. A business plan is presented in which the target market is initially human isologous islet transplantation, a clinically approved and proven procedure. Subsequently allogeneic and xenogeneic transplantation are expected to follow as these markets mature along with increased use of magnetic flow separation. Objective: Techshot proposes translational research leading to the submission of a Device Master File (DMF) to the FDA supporting use of Quadrasep as a manufacturing tool for effecting the improved isolation of human pancreatic islets of Langerhans for therapeutic transplantation for the prevention of diabetes in pancreatectomy patients. Description: The project plan includes (1) Improving the existing successful quadrupole sorter technology to meet required commercial and regulatory standards including cGMP fabrication, (2) Proving the technology through a series of human islet purifications in direct comparison with current methods using widely accepted criteria for islet evaluation, and (3) Approving the technology through application for a Device Master File with the U. S. Food and Drug Administration. The outcome of the project is expected to include the development of an instrument and consumables kit that improves the quality of islet transplants for which there is increasing demand. These outcomes, in turn, represent improved opportunities to eventually cure type-1 diabetes, which is currently only managed. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: There are more than 3 million Type 1 diabetes patients in the United States and anadditional 30,000 new patients per year. A permanent cure (insulin independence) for Type 1 diabetes has been tested on a few hundred patients in Phase 3 clinical trials. It consists of producing healthy islets of Langerhans, small bits of tissue in thepancreas that produce insulin in response to high blood sugar, from organ-donor pancreases. These islets are transplanted to the liver of the patient, who sometimes returns to normal blood sugar levels. Due to islet loss and damage during the isolation process only 26% of the transplant recipients received enough islets from one organ, and 74% of the recipients required islets from two to four donors. Separating islets by a new method, magnetic flow sorting has been shown to produce superior samples of islets. The proposed project will further demonstrate this fact and prepare the method of magnetic flow sorting for the improved manufacture of purified islets for use in cell therapies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government